Veterinary-labeled continuous interstitial glucose monitoring sensor and reader, built on off-patent first-generation amperometric glucose-oxidase sensing chemistry, with a species-specific adhesive form factor and calibration algorithm, for diabetic dogs and cats
7/9
factors scored
4/4
core factors
1/31
claims verified
1
refuted
How to read a tag. Only
verified counts toward a score — it means a typed connector
resolved this against a primary US federal record.
unconfirmed means the Verifier checked and could not confirm,
which very often means the source could not be queried at all rather than that
the claim is doubtful. refuted means a primary source
contradicts it. unverified means nothing has checked it yet.
claim 1verifiedUS
21 CFR 807.65(b) exempts a manufacturer of devices to be used solely for veterinary purposes from FDA device establishment registration requirements.
jurisdiction: US — confidence: verified — source: regulation 807.65 --expect "veterinary purposes" --jurisdiction US → eCFR versioner title-21, issue 2026-08-19, section=807.65. Full text of paragraph (b): "A manufacturer of devices to be used solely for veterinary purposes" — exact phrase match, not a paraphrase.…the full check Corroborating re-verification of the frontmatter's broader "n/a — FDA does not premarket-review animal-only devices" reasoning: regulation 807.20 --expect "human use" → verified (807.20(a) registration duty attaches only to "a device intended for human use"); regulation 807.81 --expect "human use" → verified (807.81(a) premarket-notification duty attaches only to registrants under 807.20, for "a device intended for human use"); regulation 814.1 --expect "human use" → verified (814.1(a) PMA duty is scoped to "medical devices intended for human use"). All four sections independently confirm the chain: registration, 510(k), and PMA obligations attach only to human-use devices, and veterinary-only manufacturers are explicitly exempted from registration. Also ran classification --device-name "veterinary glucose monitor" --jurisdiction US → unconfirmed, no record found — consistent with (not proof of) FDA's classification database containing no veterinary device entries, since openFDA classification covers human-use devices only.
claim 2refutedUS
21 CFR 862.1355 is FDA's classification regulation for a "Glucose test system," Class II, and covers human-labeled glucose monitoring products including continuous glucose monitors.
jurisdiction: US — confidence: refuted — note: partially — see split below — source: the section number and the device-type name are mismatched.regulation 862.1355 --expect "glucose test system" --jurisdiction US → unconfirmed, phrase not found; the connector's own quoted text shows 862.1355 is actually titled…the full check "Integrated continuous glucose monitoring system" (iCGM), Class II special controls, adult-population MARD-style accuracy criteria. A follow-up regulation 862.1345 --expect "glucose test system" --jurisdiction US → verified, eCFR versioner title-21, issue 2026-08-19, section=862.1345 — this section, not 862.1355, is titled "§ 862.1345 Glucose test system," Class II. classification --device-name "continuous glucose monitoring system" --jurisdiction US → verified, openFDA device/classification product_code=QLG, "Integrated Continuous Glucose Monitoring System... (regulation 862.1355, review panel CH)" — confirming 862.1355 is real, Class II, and does cover CGM products (Libre/Dexcom-type analogs), but under its own distinct name, not under the name "Glucose test system" the claim attributes to it. Net: refuted as stated — the claim conflates two adjacent, differently-named Class II regulations (862.1345 "Glucose test system" vs. 862.1355 "Integrated continuous glucose monitoring system"). This does not undermine the substantive counterfactual purpose the frontmatter uses this citation for (Class II, human-use CGM products exist and are classified) — that substance is verified — but the specific section-to-name pairing in this claim line is wrong and should be corrected to cite 862.1355 by its actual name if retained as the CGM counterfactual, or cite 862.1345 if "Glucose test system" specifically is meant.
claim 3unconfirmedUS
Abbott's FreeStyle Libre continuous glucose monitor is used off-label in veterinary practice in diabetic cats and dogs, and multiple published veterinary studies have tested its accuracy in this off-label use, including a 2025 study on the FreeStyle Libre 3 in cats.
jurisdiction: US — confidence: unconfirmed — source: no connector in this repo checks published-literature claims at Stage 3 depth.literature / literature-detail exist, but per connectors/result.py they are Stage 0 scan tools that return a ScanResult (found/none/unavailable), which structurally carries no…the full check confidence tag and has no to_claim_line() — a scan record is a pointer to go check, not itself a verified/refuted answer, by design (see result.py's scan/claim separation, and CLAUDE.md "the one rule that matters"). The Generator also did not capture specific PMIDs, so even a Stage 0 literature-detail pull couldn't be pointed at a specific record. Stays unconfirmed; would need a human or Stage 0 pass to surface real PMIDs, followed by a documented primary-source read (not a connector call, since none exists for this claim type).
claim 4unconfirmedUS
Published veterinary studies report that off-label human CGM devices reliably measure normal and high glucose values in dogs and cats but show more variability at low (hypoglycemic) glucose values.
jurisdiction: US — confidence: unconfirmed — source: same gap as the claim above — no typed connector in this repo reaches published clinical/veterinary literature findings at Stage 3; literature/literature-detail are Stage 0 scans that produce no confidence-tagged result. No PMIDs were supplied to even attempt a…the full check Stage 0 pull. Stays unconfirmed pending a human primary-source read.
claim 5unconfirmedUS
The enzymatic glucose-oxidase amperometric sensing mechanism underlying first-generation continuous glucose monitors (e.g. Dexcom SEVEN Plus, Abbott FreeStyle Navigator) traces to electrochemical glucose-oxidase enzyme-electrode research from the early-to-mid 1960s (Clark and Lyons) through the late 1960s (Updike and Hicks).
jurisdiction: US — confidence: unconfirmed — source: this is a technology-history/attribution claim with no specific patent number, publication, or product attached, so no connector in this repo reaches it: patent requires an exact patent_id to look up (there isn't one named here — nothing to query), and…the full check literature-history claims of this kind fall outside the Stage-0-scan/Stage-3-connector split entirely (no publication identifier given either). Stays unconfirmed.
claim 6unconfirmedUS
No specific patent number, holder, or expiration date for any foundational or manufacturing-process CGM sensor patent has been identified by the Generator; freedom to operate on the sensing chemistry, the adhesive/insertion mechanism, and the calibration algorithm is an open question requiring a real patent search, not something this candidate can assume clear.
jurisdiction: US — confidence: unconfirmed — source: attempted via the patent connector rather than left unattempted, as required: patent US3539455A --jurisdiction US (a probe call — no real patent number is claimed by the Generator, so there is nothing legitimate to look up; this call exists only to test whether…the full check the connector path is even reachable) → {"status": "unconfirmed", "source_ref": null, "detail": "PATENTSVIEW_API_KEY not set — request one at https://patentsview.org/apis/keyrequest before running Stage 3 IP checks"}. Two independent reasons this stays unconfirmed rather than being resolved either way: (1) the claim's own premise is that no specific patent has been identified, so there is no patent_id for a real FTO search; (2) even if one were supplied, PATENTSVIEW_API_KEY is not set in this environment, so connectors/patents.py returns unconfirmed unconditionally regardless of input. This is a live, unresolved FTO gap, not a settled "clear" — flag for Scores/Gate Check as an open FTO question, and set the key before trusting any future patent check on this file.
claim 7unconfirmedUS
The American Veterinary Medical Association and veterinary endocrinology literature identify diabetes mellitus as a common endocrine disease in dogs and cats, but the Generator has not located and cites no specific prevalence figure or diagnosed-case count here.
jurisdiction: US — confidence: unconfirmed — source: no connector in this repo reaches veterinary epidemiological/prevalence data — procedures only serves Medicare fee-for-service human utilization data, which has no bearing on a dog/cat population, and no AVMA-equivalent connector exists. Stays unconfirmed; would…the full check need a human-attached veterinary epidemiology source (e.g., Banfield/BluePearl State of Pet Health report).
claim 8unconfirmedUS
TAM decomposition, each piece separately checkable in principle: (a) number of dogs and cats in the US currently diagnosed with and under treatment for diabetes mellitus — not established here; (b) estimated price per sensor/reader unit if sold at a premium to veterinary clinics or pet owners, modeled loosely on human CGM cash-pay pricing — not established here, no specific figure sourced; (c) addressable share assuming some fraction of diagnosed, insulin-treated pets are monitored with serial blood glucose curves today and could plausibly switch — not established here, and note this share depends on owner and clinician willingness to pay, which is an assumption, not a fact (see next claim).
jurisdiction: US — confidence: unconfirmed — source: market "TAM decomposition for veterinary CGM: diagnosed diabetic dog/cat population x per-unit price x addressable share" → {"status": "unverifiable", ...} (market claims always return unverifiable by design; mapped to unconfirmed per the tag vocabulary).…the full check Checked whether this decomposes further into a checkable proxy per the connector guidance: procedures (Medicare FFS utilization) is the tool for sub-figure (a) on a human analog, but this population is dogs and cats — not Medicare beneficiaries — so procedures has no applicable code here and cannot supply a floor figure the way it would for a human-condition TAM claim. All three sub-figures ((a) diagnosed diabetic pet population, (b) per-unit price, (c) addressable share) remain fully unconfirmed; no connector in this repo reaches veterinary-population or veterinary-pricing data.
claim 9unconfirmedUS
Assumption, not a fact: veterinary owners and clinicians would be willing to pay a premium price, out of pocket (pet insurance reimbursement for devices is inconsistent and not established here), for continuous glucose monitoring over the current standard of serial blood-glucose-curve sampling. This is a stated design assumption behind the TAM decomposition above, not a claim any connector in this repo can check.
jurisdiction: US — confidence: unconfirmed — source: adoption "Veterinary owners and clinicians would be willing to pay a premium out-of-pocket price for continuous glucose monitoring over serial blood-glucose-curve sampling" → {"status": "unverifiable", ...} — adoption/preference claims always come back…the full check unverifiable by design (no primary research exists in this repo, and none was substituted here per the explicit prohibition on producing a synthetic stakeholder opinion). Mapped to unconfirmed. Not rescoped to a checkable proxy for this pass because no pet-insurance coverage connector exists and procedures does not reach veterinary volumes (see claim above) — there is no proxy in this repo's connector set for this particular claim.
claim 10unconfirmedUS
Because veterinary devices are not FDA premarket-reviewed, there is no CPT/HCPCS-style federal payer code or coverage policy applicable to this product; reimbursement, where it exists at all, would run through pet-insurance policies rather than Medicare or a federal payer, and no connector in this repo reaches that data.
jurisdiction: US — confidence: unconfirmed — source: probed hcpcs A4239 --expect "glucose monitor" --jurisdiction US (a representative human CGM-adjacent HCPCS code, used only to test whether the connector path is reachable, not because this code is claimed for this product) → `{"status": "unconfirmed",…the full check "source_ref": null, "detail": "No local cache at data/hcpcs_level_ii.csv..."} — the data/ directory in this repo currently has no cached HCPCS/payment/coverage files at all (only data/README.md), so hcpcs/payment/coverage cannot resolve any code right now, human or veterinary. More fundamentally, HCPCS/Medicare payment/NCD-LCD coverage are all human-Medicare/Medicaid federal-payer systems with no veterinary analog in this repo's connector set — there is no "does a veterinary HCPCS code exist" question to ask these tools, which is consistent with the claim's own assertion that no connector here reaches pet-insurance reimbursement data. Stays unconfirmed on both counts. [Verifier note, this pass: re-ran the same probe — data/ still contains only README.md, no HCPCS/payment/coverage cache exists, and PATENTSVIEW_API_KEY`-style "attach a file" gaps aside, there remains no veterinary-payer connector of any kind in this repo. Nothing further to check; tag and reasoning stand unchanged.]
claim 11unconfirmedUS
In 20 client-owned diabetic cats (288 paired readings), the FreeStyle Libre 3 showed a mean absolute relative difference (MARD) of 13.6% against a portable blood glucose meter reference, with 99.7% (287/288) of paired readings in Parkes error-grid zones A+B, and provided clinically accurate measurements in the euglycemic and hyperglycemic ranges
jurisdiction: US — confidence: unconfirmed — source: literature-detail 41742494 → PMID resolves; PubMed PMID=41742494, "Evaluation of the FreeStyle Libre 3 in client-owned diabetic cats," J Vet Intern Med (2026). Retrieved abstract confirms every figure in this claim verbatim: 20 client-owned diabetic cats, 288…the full check paired IG-BG measurements, MARD 13.6%, 99.7% (287/288) in Parkes EGA zones A+B, "clinically accurate measurements in the euglycemic and hyperglycemic ranges." Stays unconfirmed, not verified: literature-detail returns a Stage 0 ScanResult (per connectors/result.py and CLAUDE.md's scan/claim separation), which structurally has no to_claim_line() and cannot carry a confidence tag — an abstract match is a strong lead, not a Stage 3 appraisal (no methods review, no risk-of-bias check, no funding disclosure). No typed connector in this repo reaches published-finding depth (the research-lane-spec's proposed corroborated tag for class-2 evidence is still pending human decision, §6). Citation: PubMed PMID=41742494.
claim 12unconfirmedUS
In a hyperinsulinemic-hypoglycemic clamp study in 7 purpose-bred cats (474 paired measurements), the FreeStyle Libre 3 did not achieve analytical accuracy but demonstrated 99-100% clinical accuracy (Parkes EGA zones A+B); it underestimated blood glucose in euglycemia and mild hypoglycemia but overestimated blood glucose in marked hypoglycemia (<55 mg/dL)
jurisdiction: US — confidence: unconfirmed — source: literature-detail 40105400 → PMID resolves; PubMed PMID=40105400, "Accuracy of the Freestyle Libre 3 Continuous Glucose Monitoring System in Hypo- and Euglycemic Cats," J Vet Intern Med (2025). Abstract confirms verbatim: 7 healthy purpose-bred cats, n=474 paired…the full check measurements, hyperinsulinemic-hypoglycemic clamps, analytical accuracy not achieved, 99-100% in Parkes EGA zones A+B, underestimation in euglycemia/mild hypoglycemia, overestimation in marked hypoglycemia (<55 mg/dL). Stays unconfirmed for the same structural reason as the claim above — literature-detail is a Stage 0 scan tool, not a confidence-tagged Stage 3 connector. Citation: PubMed PMID=40105400.
claim 13unconfirmedUS
In 34 predominantly diabetic cats wearing 66 FreeStyle Libre sensors, 70% (46/66) of sensors stopped functioning in situ before the end of the labeled 14-day wear period, with a median functional life of 8.3 days (range 1.6-14), and the device's display showed 'Hi' (above its 500 mg/dL measurement ceiling) repeatedly and/or for periods exceeding 1 hour in 62% (17/34) of the cats
jurisdiction: US — confidence: unconfirmed — source: literature-detail 33229057 → PMID resolves; PubMed PMID=33229057, "Use of the 'FreeStyle Libre' glucose monitoring system in diabetic cats," Res Vet Sci (2021). Abstract confirms verbatim: 66 sensors on 34 predominantly diabetic cats, 70% (46/66) stopped working…the full check in situ, median functional life 8.3 (1.6-14) days, "Hi" displayed repeatedly and/or for periods >1h in 62% (17/34) of cats. Stays unconfirmed — same structural reason as above. Citation: PubMed PMID=33229057.
claim 14unconfirmedUS
Flash glucose monitoring system (FreeStyle Libre 2) accuracy in dogs is skin-thickness dependent: in a prospective study of 14 client-owned diabetic dogs, clinical accuracy (99% of readings in Parkes consensus error-grid zones A+B, per ISO 15197:2013 criteria) was observed only in dogs with ultrasound-measured skin thickness >5mm, while dogs with skin thickness <5mm showed low accuracy requiring cautious interpretation
jurisdiction: US — confidence: unconfirmed — source: literature-detail 33562672 → PMID resolves; PubMed PMID=33562672, "The Influence of Skin Thickness on Flash Glucose Monitoring System Accuracy in Dogs with Diabetes Mellitus," Animals (2021). Abstract confirms the substantive figures verbatim: 14 client-owned…the full check diabetic dogs, ISO 15197:2013 criteria, 99% in Parkes zones A+B only in the >5mm skin-thickness group, low accuracy/cautious interpretation in the <5mm group. One gap worth flagging: the retrieved abstract refers throughout to a generic "flash glucose monitoring system (FGMS)" and never names "FreeStyle Libre 2" specifically — the claim's device-generation attribution is not itself confirmed by this abstract (may be named in the full-text methods, not retrievable via this connector). Stays unconfirmed — same structural reason as above, compounded here by the unconfirmed device-generation detail. Citation: PubMed PMID=33562672.
claim 15unconfirmedUS
In a prospective study of 23 healthy dogs with insulin-induced hypoglycemia, the FreeStyle Libre 2 flash glucose monitoring system showed limited analytical accuracy against a reference clinical chemistry analyzer (50.9% of readings within +/-15 mg/dL of reference, versus 67.2% for a portable blood glucose meter), but 88.6% of FGMS readings fell within Parkes error-grid zones A+B and the system rarely produced readings likely to lead to detrimental clinical decisions
jurisdiction: US — confidence: unconfirmed — source: literature-detail 40280161 → PMID resolves; PubMed PMID=40280161, "The FreeStyle Libre 2 system demonstrates limited analytical accuracy without resulting in detrimental clinical decisions," Am J Vet Res (2025) — title itself names FreeStyle Libre 2, resolving the…the full check generation-attribution gap noted on the claim above. Abstract confirms verbatim: 23 healthy dogs, insulin-induced hypoglycemia, 50.9% FGMS vs 67.2% PBGM within ±15 mg/dL of reference, 88.6% FGMS in Parkes zones A+B, "rarely produced glucose readings likely to lead to detrimental clinical decisions." Stays unconfirmed — same structural reason as above. Citation: PubMed PMID=40280161.
claim 16unconfirmedUS
A 2010 review of glucose biosensor technology states the amperometric glucose-oxidase biosensor concept was first proposed in 1962 by Clark and Lyons, and that Updike and Hicks (1967) advanced it practically by immobilizing and stabilizing glucose oxidase in a polyacrylamide gel on an oxygen electrode, enabling glucose measurement in biological fluids
jurisdiction: US — confidence: unconfirmed — source: literature-detail 22399892 → PMID resolves; PubMed PMID=22399892, "Glucose biosensors: an overview of use in clinical practice," Sensors (Basel) (2010), tagged Historical Article/Review — journal, date, and article type are all consistent with a 2010 historical…the full check review of biosensor technology. However, the retrieved abstract is only a high-level summary ("reviews the brief history, basic principles... of glucose biosensors in clinical practice") and does not itself state the specific Clark-and-Lyons-1962 / Updike-and-Hicks-1967 attribution the claim asserts — that level of detail, if present, is in the full-text body, which this connector cannot reach. Weaker confirmation than the claims above: PMID, journal, date, and general subject match, but the specific historical attribution is unconfirmed by what was retrieved. Stays unconfirmed regardless — same structural reason (Stage 0 ScanResult, no confidence tag) — with the added caveat that even a full abstract match would not have changed the tag. Citation: PubMed PMID=22399892.
claim 17unconfirmedUS
US veterinary teaching hospital (VMDB) records show hospital-presented diabetes mellitus prevalence in dogs rose from 19 to 64 cases per 10,000 admissions per year between 1970 and 1999 (n=6,860 DM dogs identified, 6,707 matched controls); this figure is dated (through 1999) and reflects hospital presentation, not a current general-population prevalence estimate
jurisdiction: US — confidence: unconfirmed — source: literature-detail 12672370 → PMID resolves; PubMed PMID=12672370, "Time trends and risk factors for diabetes mellitus in dogs: analysis of veterinary medical data base records (1970-1999)," Vet J (2003). Abstract confirms verbatim: 6,860 dogs with DM diagnosis…the full check (1970-1999), 6,707 matched controls, hospital prevalence rising from 19 to 64 cases per 10,000 admissions/year. (Abstract also reports case-fatality falling from 37% to 5% — additional content the claim line didn't restate, not a discrepancy.) Stays unconfirmed — same structural reason as above. Citation: PubMed PMID=12672370.
claim 18unconfirmedUS
US veterinary teaching hospital (VMDB) records show hospital-presented diabetes mellitus prevalence in cats rose from 8 to 124 cases per 10,000 admissions between 1970 and 1999, with case-fatality at first visit falling from 40% to 10% over the same period; this figure is dated (through 1999) and reflects hospital presentation, not a current general-population prevalence estimate
jurisdiction: US — confidence: unconfirmed — source: literature-detail 17449313 → PMID resolves; PubMed PMID=17449313, "Time trends and risk factors for diabetes mellitus in cats presented to veterinary teaching hospitals," J Feline Med Surg (2007). Abstract confirms verbatim: hospital prevalence rising from 8 to…the full check 124 cases per 10,000 (1970-1999), case-fatality at first visit falling from 40% to 10%. Stays unconfirmed — same structural reason as above. Citation: PubMed PMID=17449313.
claim 19unconfirmedUS
One veterinary clinic's own published pricing for pet use states a FreeStyle Libre sensor (used for up to 14 days) costs $75.08 each; this is a single-clinic data point, not a systematic price survey, and is offered alongside (not as a substitute for) Abbott's own human-patient cost page, which states insured human patients typically pay $0-20/sensor and cites a copay-card threshold of 'over $75 for two sensors' for uninsured human patients
jurisdiction: US — confidence: unconfirmed — source: no connector in this repo reaches a single-clinic retail-pricing page or a manufacturer's consumer cost page — neither is a US federal registry or a PubMed record, so none of hcpcs/payment/coverage/literature-detail apply. Probed `market "FreeStyle Libre…the full check veterinary sensor retail pricing per-unit cost $75.08" → {"status": "unverifiable", "detail": "...has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report..."} — market-type claims always return unverifiable by design. Stays unconfirmed`; would need a human-attached, systematic pricing survey (not one clinic's posted price) to move further. Citation: none available at Stage 3 depth; source URLs as stated in the claim (craigrd.com clinic page; Abbott patient cost page) remain secondary, unverified sources.
claim 20unconfirmedUS
In a 2023 survey of 50 diabetic-pet owners already using an off-label flash glucose monitoring system (FreeStyle Libre), more than 80% rated it easier to use and less stressful/painful for the animal than blood-glucose-curve sampling, and 92% reported better diabetes control since switching; the same owners named sensor fixation (47%), preventing premature detachment (40%), long-term affordability (36%), and difficulty purchasing the sensor (34%) as the most challenging aspects of continued use — revealed adoption and friction behavior with an already-existing off-label product, offered as the answerable twin to the unanswerable question of whether owners/clinicians would pay a premium for this candidate's not-yet-built product
jurisdiction: US — confidence: unconfirmed — source: literature-detail 36977242 → PMID resolves; PubMed PMID=36977242, "Monitoring of Diabetes Mellitus Using the Flash Glucose Monitoring System: The Owners' Point of View," Vet Sci (2023). Abstract confirms verbatim: 50-diabetic-pet-owner survey, >80% rated FGMS…the full check easier/less stressful than BGCs, 92% reported better control, challenges named as sensor fixation (47%), preventing premature detachment (40%), purchasing the sensor (34%). One nuance, not a numeric error: the claim groups "long-term affordability (36%)" into the same ranked list as the other three percentages, but the abstract states this 36% figure in a separate sentence ("36% of DPOs reported that the device cost was difficult to afford in the long term") rather than as a fourth item in the same ranked list — the figure and its substance are both present, just differently framed. (Abstract also reports a dog-vs-cat tolerability breakdown not carried into this claim — additional content, not a discrepancy.) Stays unconfirmed — same structural reason as the claims above; correctly reframed here as the checkable class-2 proxy for an otherwise-unanswerable adoption question, consistent with connectors/adoption.py's own guidance to look for revealed-preference literature instead of a synthetic stakeholder opinion. Citation: PubMed PMID=36977242.
claim 21unconfirmedUS
openFDA records 10 device recalls (2016-2026) under product code QLG (the human-labeled 'Integrated continuous glucose monitoring system' regulation this candidate's off-label analog falls under), including recall Z-2692-2024, initiated 2024-07-24 for FreeStyle Libre 3 sensors reporting erroneously high glucose results with a stated risk of missed or delayed hypoglycemia detection
jurisdiction: US — confidence: unconfirmed — source: recalls --product-code QLG --since 2024-07-01 --until 2024-08-15 → found; record Z-2692-2024, event_date_initiated=2024-07-24, Abbott Diabetes Care, FreeStyle Libre 3 Sensors REF 72081-01, reason: "erroneously high glucose results... may lead to... missed or…the full check delayed recognition of hypoglycemia," FDA root cause: Process design, related 510(k) K212132 — every fact in this claim line matches the primary openFDA record exactly. The broader "10 recalls (2016-2026)" total was not independently re-swept here (would require a full 10-year unfiltered pull); the one specific record cited is confirmed. Stays unconfirmed, not verified: connectors/recalls.py is explicitly documented as a Stage 0 (Scout) scan returning a ScanResult — "never evidence for a claim" per its own module docstring — structurally incapable of to_claim_line()/a confidence tag, same limitation as the literature claims above. This is a strong, fact-checked lead with no discrepancy found, but the repo has no Stage 3 connector for recall-record facts. Citation: openFDA device/recall product_res_number=Z-2692-2024.
claim 22unconfirmedUS
openFDA records recalls Z-1020-2026, Z-1021-2026, Z-1022-2026, and Z-1023-2026 (all initiated 2025-11-24, product code QLG), covering FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors, for a manufacturing process issue causing carbon buildup in the sensor that may result in incorrect low glucose results
jurisdiction: US — confidence: unconfirmed — source: recalls --product-code QLG --since 2025-11-01 --until 2025-12-15 → found; all four record numbers, dates, and reasons confirmed exactly against the primary source: Z-1020-2026 (FreeStyle Libre 3 Sensor REF 72081-01), Z-1021-2026 (FreeStyle Libre 3 Plus Sensor REF…the full check 78768-01), Z-1022-2026 (FreeStyle Libre 3 Plus Sensor REF 78769-01), Z-1023-2026 (FreeStyle Libre 3 Plus Sensor REF 72080-01), all event_date_initiated=2025-11-24, all reason="manufacturing process issue that may cause carbon build up in the sensor that may result in incorrect low glucose results," FDA root cause: Process control. No discrepancy found. Stays unconfirmed, same structural reason as the claim above — recalls is a Stage 0 ScanResult tool, not a confidence-tagged Stage 3 connector. Citation: openFDA device/recall product_res_number=Z-1020-2026 (and Z-1021-2026, Z-1022-2026, Z-1023-2026).
claim 23unconfirmedUS
openFDA records recall Z-1275-2023, initiated 2023-02-13 (product code QLG), for FreeStyle Libre reader units (REF 71951-01/71952-01/71953-01) whose lithium-ion batteries may swell, overheat, or pose a fire hazard
jurisdiction: US — confidence: unconfirmed — source: recalls --product-code QLG --since 2023-01-15 --until 2023-03-15 → found; record Z-1275-2023, event_date_initiated=2023-02-13, Abbott Diabetes Care, FreeStyle Libre Reader REF 71951-01/71952-01/71953-01, reason: "Lithium-ion batteries in glucose monitoring system…the full check readers may swell, overheat, or pose fire hazard," FDA root cause: Device Design, related 510(k) K193371 — every fact in this claim line matches the primary openFDA record exactly. (The same scan window also surfaced an unrelated recall, Z-0734-2024, an Android-app signal-loss issue — not cited by this claim and not needed to confirm it.) Stays unconfirmed, same structural reason as the two claims above. Citation: openFDA device/recall product_res_number=Z-1275-2023.
claim 24unconfirmedUS
In a random sample of 1,053 confirmed diabetes mellitus cases drawn from 1,225,130 cats under primary veterinary care in the United Kingdom in 2019 (VetCompass), annual period prevalence was 0.39% (95% CI 0.37-0.42) and incidence risk was 0.14% (95% CI 0.13-0.16); this is a non-US, primary-care population and is offered as a more recent, larger-scale comparator to the dated (through 1999) US hospital-presentation figures, not a US prevalence estimate
jurisdiction: US — confidence: unconfirmed — source: literature-detail 40525629 → PMID resolves; PubMed PMID=40525629, "Frequency, Risk Factors, and Mortality for Diabetes Mellitus in 1,225,130 Cats Under Primary Veterinary Care in the United Kingdom in 2019," J Vet Intern Med (2025). Abstract confirms verbatim:…the full check 1,053 confirmed DM cases (random sample), VetCompass, annual prevalence 0.39% (95% CI 0.37-0.42), incidence risk (2019) 0.14% (95% CI 0.13-0.16). Discrepancy worth flagging, however small: the retrieved title states the cohort denominator as "1,225,130 Cats" (matching the claim as written), but the abstract's own [ANIMALS] section states the random sample of 1,053 DM cases was drawn "from 1,255,130 cats" — a different figure (1,255,130, not 1,225,130) inside the same retrieved record. This is an inconsistency in the source record itself (title vs. body), not an error introduced by the claim drafter, but the claim's stated denominator matches only the title, not the body text of its own cited abstract. Flag for a human to resolve against the published PDF (likely a digit-transposition typo in one field or the other) before treating either figure as settled. All other figures (case count, prevalence, incidence, CIs) match exactly. Stays unconfirmed: literature-detail is a Stage 0 ScanResult tool (per connectors/result.py and CLAUDE.md's scan/claim separation) with no to_claim_line(), structurally incapable of carrying a Stage 3 confidence tag regardless of match quality. Citation: PubMed PMID=40525629.
claim 25unconfirmedUS
Japanese pet-insurance claims data show canine diabetes mellitus prevalence rising from approximately 0.07% of insured dogs in 2015 to 0.30% in 2023, a trend confirmed by logistic regression (odds ratio 1.128 per year, 95% CI 1.116-1.142, p<0.001, a 12.8% annual increase in the odds of diabetes); this is a non-US, insurance-claims-based comparator, not a US prevalence estimate
jurisdiction: US — confidence: unconfirmed — source: literature-detail 41443822 → PMID resolves; PubMed PMID=41443822, "Increase in the prevalence of canine diabetes mellitus in Japan from 2015 to 2023: insights from insurance and clinical data," J Vet Med Sci (2026). Abstract confirms verbatim: pet-insurance-claims…the full check dataset, prevalence rising from ~0.07% (2015) to 0.30% (2023), logistic regression, odds ratio 1.128 (95% CI 1.116-1.142), "annual 12.8% increase in the odds of diabetes." No discrepancy found — every figure in the claim matches the retrieved abstract exactly (the abstract additionally reports a secondary new-enrollee-only OR of 1.097 and a male-vs-female prevalence disparity, neither restated in the claim — additional content, not a conflict). Stays unconfirmed for the same structural reason as the claim above — literature-detail is a Stage 0 scan tool, not a confidence-tagged Stage 3 connector. Citation: PubMed PMID=41443822.
claim 26unverifiedUS
A species-specific haired-skin adhesive sensor form factor achieves a premature failure/detachment rate in diabetic dogs and cats lower than the 70% (46/66) premature-failure rate documented for off-label FreeStyle Libre sensors in diabetic cats, whose median functional life was 8.3 days (range 1.6-14).
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (desirability deck, 2026-08-30) — never checked; recorded so the Verifier can see it
claim 27unverifiedUS
A veterinarian would rely on this device for hypoglycemia detection in dogs and cats despite the low-glucose overestimation bias documented in marked hypoglycemia (<55 mg/dL) for the same underlying off-label sensing technology in cats.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (desirability deck, 2026-08-30) — never checked; recorded so the Verifier can see it
claim 28unverifiedUS
ALR Technologies' GluCurve Pet CGM, a purpose-built veterinary continuous glucose monitor, is commercially available to US veterinary practices and pet owners at a price and accuracy competitive with this candidate's launch position.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (viability deck, 2026-08-30) — never checked; recorded so the Verifier can see it
claim 29unverifiedUS
The absence of FDA premarket review for a veterinary-only device materially reduces this candidate's development cost and calendar time-to-revenue compared to an equivalent human-labeled continuous glucose monitor.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (viability deck, 2026-08-30) — never checked; recorded so the Verifier can see it
claim 30unverifiedUS
The candidate's species-specific calibration algorithm corrects the low-glucose overestimation bias in marked hypoglycemia (<55 mg/dL) and the skin-thickness-dependent accuracy loss documented for the off-label, human-calibrated FreeStyle Libre in diabetic cats and dogs.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (feasibility deck, 2026-08-30) — never checked; recorded so the Verifier can see it
claim 31unverifiedUS
The candidate's adhesive and sensor materials are biocompatible for repeated subcutaneous placement and adhesive contact on clipped or fur-parted haired canine and feline skin, without the sensor-detachment and premature-failure rates documented for off-label FreeStyle Libre use in diabetic cats.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (feasibility deck, 2026-08-30) — never checked; recorded so the Verifier can see it